Colleen Reitan

Track

Insider profile

Currently holds a position at Alnylam Pharmaceuticals Inc

Performance

Overall performance
1.1
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -13% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
3 67% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return -19%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Alnylam Pharmaceuticals Inc Dec. 1, 2018 -
Director Alnylam Pharmaceuticals Inc June 1, 2018 - Dec. 1, 2018
Colleen Reitan's trades of Alnylam Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
461.12
Quantity 18,000
Value US$8,300,070
Transaction date
Planned sale
Price
27.95
Quantity 46,012 -52.0%
Value US$1,285,851
Transaction date
Proposed sale
Price
28.19
Quantity 46,012
Value US$1,297,078
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-09-11 2025-09-09
PlS Planned sale
63,013 +15.2%
81.95
US$3,170,619 		63,013 +15.2% 81.95 US$3,170,619
2025-09-11 2025-09-09
PlS Planned sale
29,182 +20.9%
364.56
US$2,910,143 		29,182 +20.9% 364.56 US$2,910,143
2025-09-11 2025-09-09
PlS Planned sale
77,039 +41.0%
477.83
US$2,057,757 		77,039 +41.0% 477.83 US$2,057,757
2025-09-11 2025-09-09
PlS Planned sale
1,183 -24.5%
477.47
US$564,847 		1,183 -24.5% 477.47 US$564,847
2025-09-11 2025-09-09
PlS Planned sale
972 -16.8%
476.31
US$462,973 		972 -16.8% 476.31 US$462,973
2025-09-11 2025-09-09
PlS Planned sale
951 -14.1%
474.85
US$451,582 		951 -14.1% 474.85 US$451,582
2025-09-11 2025-09-09
PlS Planned sale
838 -11.1%
474.22
US$397,396 		838 -11.1% 474.22 US$397,396
2025-09-11 2025-09-09
PlS Planned sale
823 -9.8%
472.82
US$389,131 		823 -9.8% 472.82 US$389,131
2025-09-11 2025-09-09
PlS Planned sale
222 -2.6%
471.25
US$104,618 		222 -2.6% 471.25 US$104,618
2025-09-11 2025-09-09
PlS Planned sale
799 -8.5%
464.36
US$371,024 		799 -8.5% 464.36 US$371,024
2025-09-11 2025-09-09
PlS Planned sale
1,652 -14.9%
463.00
US$764,876 		1,652 -14.9% 463.00 US$764,876
2025-09-11 2025-09-09
PlS Planned sale
2,290 -17.1%
461.92
US$1,057,797 		2,290 -17.1% 461.92 US$1,057,797
2025-09-11 2025-09-09
PlS Planned sale
473 -3.4%
460.71
US$217,916 		473 -3.4% 460.71 US$217,916
2025-09-11 2025-09-09
PlS Planned sale
1,403 -9.2%
459.73
US$645,001 		1,403 -9.2% 459.73 US$645,001
2025-09-11 2025-09-09
PlS Planned sale
1,888 -11.0%
458.86
US$866,328 		1,888 -11.0% 458.86 US$866,328
2025-09-11 2025-09-09
PlS Planned sale
1,645 -8.8%
457.44
US$752,489 		1,645 -8.8% 457.44 US$752,489
2025-09-09 2025-09-09
PrS Proposed sale
18,000
461.12
US$8,300,070 		18,000 461.12 US$8,300,070
2025-05-12 2025-04-16
S Sale
36 -100.0%
232.86
US$8,383 		36 -100.0% 232.86 US$8,383
2025-05-12 2024-10-17
B Purchase
4 +12.5%
302.67
US$1,211 		4 +12.5% 302.67 US$1,211
2024-09-04 2024-09-03
PlS Planned sale
46,012 -52.0%
27.95
US$1,285,851 		46,012 -52.0% 27.95 US$1,285,851
2024-09-03 2024-09-03
PrS Proposed sale
46,012
28.19
US$1,297,078 		46,012 28.19 US$1,297,078
2025-05-12 2024-08-29
B Purchase
32 +inf%
286.00
US$9,152 		32 +inf% 286.00 US$9,152